Format

Send to

Choose Destination
Hosp Med. 2003 Aug;64(8):473-8.

The place of ezetimibe in clinical practice.

Author information

1
Department of Cardiology, Singleton Hospital, Swansea SA2 8QA.

Abstract

Ezetimibe is the first selective cholesterol absorption inhibitor to be licensed in the UK. It interferes both with dietary cholesterol absorption and the enterohepatic circulation of cholesterol synthesized by the liver. As monotherapy it leads to modest reductions in plasma low-density lipoprotein cholesterol levels, but has synergistic effects when used with statins.

PMID:
12958759
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center